What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Heikki Joensuu focuses on Internal medicine, Pathology, Cancer, Oncology and Surgery.
His study connects Gastroenterology and Internal medicine.
His Pathology study combines topics in areas such as Angiogenesis and Metastasis.
His Cancer research is mostly focused on the topic Breast cancer.
Heikki Joensuu interconnects Tumor-infiltrating lymphocytes, Clinical endpoint, Stage, Survival analysis and Risk factor in the investigation of issues within Oncology.
His Surgery research integrates issues from GiST and Imatinib mesylate.
His most cited work include:
- Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. (3544 citations)
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor (1920 citations)
- Effect of the Tyrosine Kinase Inhibitor STI571 in a Patient with a Metastatic Gastrointestinal Stromal Tumor (1777 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Internal medicine, Oncology, Breast cancer, Cancer and Cancer research.
His Internal medicine research is multidisciplinary, incorporating elements of Gastroenterology and Surgery.
His research investigates the link between Oncology and topics such as Docetaxel that cross with problems in Epirubicin.
His biological study spans a wide range of topics, including Gynecology and Pathology.
His Cancer research research is multidisciplinary, incorporating perspectives in Immunohistochemistry, Tyrosine kinase, Carcinogenesis and Cancer cell.
His Imatinib research includes elements of Stromal cell and Tyrosine-kinase inhibitor.
He most often published in these fields:
- Internal medicine (48.94%)
- Oncology (33.94%)
- Breast cancer (26.36%)
What were the highlights of his more recent work (between 2015-2021)?
- Internal medicine (48.94%)
- Oncology (33.94%)
- Breast cancer (26.36%)
In recent papers he was focusing on the following fields of study:
Heikki Joensuu spends much of his time researching Internal medicine, Oncology, Breast cancer, Cancer research and Cancer.
His Oncology research incorporates elements of Capecitabine, Proportional hazards model, Triple-negative breast cancer, Docetaxel and Imatinib.
His Breast cancer research includes themes of Stroma, Artificial intelligence and Pathology.
His Cancer research study integrates concerns from other disciplines, such as Immunohistochemistry, Apoptosis, Gene silencing and Drug resistance.
His research investigates the connection between Cancer and topics such as Cell culture that intersect with issues in Cell growth.
Heikki Joensuu has researched GiST in several fields, including Regorafenib, Clinical endpoint, Sarcoma and Imatinib mesylate.
Between 2015 and 2021, his most popular works were:
- Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† (739 citations)
- Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. (173 citations)
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (170 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
Internal medicine, Oncology, Breast cancer, Cancer research and Cancer are his primary areas of study.
In most of his Internal medicine studies, his work intersects topics such as Surgery.
His Oncology study combines topics from a wide range of disciplines, such as Chemotherapy, Docetaxel, Imatinib mesylate, Young adult and GiST.
The various areas that Heikki Joensuu examines in his Breast cancer study include Receptor, Dose escalation, Proportional hazards model and Hazard ratio.
The Cancer research study combines topics in areas such as Apoptosis and Advanced melanoma.
His work in Cancer tackles topics such as Biomarker which are related to areas like Tyrosine-kinase inhibitor, Renal cell carcinoma, Gastroenterology and Downregulation and upregulation.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
